

# New Products - Zaltrap

---

Zaltrap (**aflibercept (rch)**) is a recombinant protein consisting of sequences derived from human vascular endothelial growth factor (VEGF) receptor (1 and 2) extracellular domains fused to the Fc portion of human immunoglobulin G1 (IgG1). Aflibercept is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) K-1 mammalian expression system. Zaltrap in combination with irinotecan-fluoropyrimidine based chemotherapy is indicated in adults with metastatic colorectal cancer previously treated with an oxaliplatin containing regimen. Zaltrap is contraindicated for ophthalmic/ intravitreal use due to hyperosmotic properties of Zaltrap. Zaltrap is available in vials of 100 mg/4 mL and 200 mg/8 mg.

*This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.*